Drug Details
| General Information of the Drug (ID: DR0234) | ||||
|---|---|---|---|---|
| Name |
Empagliflozin
|
|||
| Synonyms |
Empagliflozin; 864070-44-0; JARDIANCE; BI 10773; Empagliflozin (BI 10773); BI-10773; BI10773; UNII-HDC1R2M35U; HDC1R2M35U; 1-chloro-4-(glucopyranos-1-yl)-2-(4-(tetrahydrofuran-3-yloxy)benzyl)benzene; (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-(((S)-tetrahydrofuran-3-yl)oxy)benzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol; CHEBI:82720; (1S)-1,5-anhydro-1-(4-chloro-3-{4-[(3S)-tetrahydrofuran-3-yloxy]benzyl}phenyl)-D-glucitol; (1S)-1,5-anhydro-1-C-{4-chloro-3-((4-{((3S)-oxolan-3-yl)oxy}phenyl)methyl)phenyl}-D-glucitol; Empagliflozin [USAN:INN]; MFCD22566222; Jardiance (TN); (1S)-1,5-Anhydro-1-C-[4-chloro-3-[[4-[[(3S)-tetrahydro-3-furanyl]oxy]phenyl]methyl]phenyl]-D-glucitol; Tube106; (S)-Empagliflozin D4; BI-10773;Empagliflozin; Empagliflozin (BI10773); C23H27ClO7; SCHEMBL899986; GTPL4754; CHEMBL2107830; Empagliflozin (JAN/USAN/INN); AMY1858; EX-A414; BDBM150162; BBL104150; CE0108; s8022; STL557964; US8980829, EMPAGLIFLOZIN; ZINC36520252; AKOS024464680; CCG-269242; CS-0940; DB09038; DS-9824; PB23119; VA10802; AC-27643; HY-15409; SW219120-1; X5927; C22194; D10459; Q-4526; Q5373824; Empagliflozin (BI-10773;BI 10773;BI10773); (2S,3R,4R,5S,6R)-2-(4-Chloro-3-(4-((S)-tetrahydrofuran-3-yloxy)benzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol; (2S,3R,4R,5S,6R)-2-[4-chloro-3-({4-[(3S)-oxolan-3-yloxy]phenyl}methyl)phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol; (2S,3R,4R,5S,6R)-2-[4-CHLORO-3-[[4-[(3S)-OXOLAN-3-YL]OXYPHENYL]METHYL]PHENYL]-6-(HYDROXYMETHYL)OXANE-3,4,5-TRIOL; (2S,3R,4R,5S,6R)-2-[4-Chloro-3-[[4-[(3S)-tetrahydrofuran-3-yl]oxyphenyl]methyl]phenyl]-6-(hydroxymethyl)tetrahydropyran-3,4,5-triol; D-Glucitol, 1,5-anhydro-1-C-(4-chloro-3-((4-(((3S)-tetrahydro-3-furanyl)oxy)phenyl)methyl)phenyl)-, (1S)-
Click to Show/Hide
|
|||
| Molecular Type |
Small molecule
|
|||
| Disease | Diabetes mellitus [ICD-11: 5A10] | Approved | [1] | |
| Structure |
|
Click to Download Mol2D MOL |
||
| Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | ||||
| Formula |
C23H27ClO7
|
|||
| PubChem CID | ||||
| Canonical SMILES |
C1COCC1OC2=CC=C(C=C2)CC3=C(C=CC(=C3)C4C(C(C(C(O4)CO)O)O)O)Cl
|
|||
| InChI |
1S/C23H27ClO7/c24-18-6-3-14(23-22(28)21(27)20(26)19(11-25)31-23)10-15(18)9-13-1-4-16(5-2-13)30-17-7-8-29-12-17/h1-6,10,17,19-23,25-28H,7-9,11-12H2/t17-,19+,20+,21-,22+,23-/m0/s1
|
|||
| InChIKey |
OBWASQILIWPZMG-QZMOQZSNSA-N
|
|||
| CAS Number |
CAS 864070-44-0
|
|||
| ChEBI ID | ||||
| TTD Drug ID | ||||
| DrugBank ID | ||||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug | ||||||
| Metformin | Galega officinalis | Click to Show/Hide the Molecular Data of This NP | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [2] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Experimental
Result(s) |
Initial combinations of empagliflozin + metformin for 24 weeks significantly reduced HbA1c versus empagliflozin once daily and metformin twice daily, without increased hypoglycemia, reduced weight versus metformin twice daily, and were well tolerated. | |||||
| Target and Pathway | ||||
|---|---|---|---|---|
| Target(s) | Sodium/glucose cotransporter 2 (SGLT2) | Molecule Info | [3] | |
| Reactome | Hexose transport | Click to Show/Hide | ||
| 2 | Na+-dependent glucose transporters | |||
| 3 | Inositol transporters | |||
| WikiPathways | NRF2 pathway | Click to Show/Hide | ||
| 2 | Nuclear Receptors Meta-Pathway | |||
| 3 | Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds | |||
